Hormonal Therapy Cardiovascular Risk
Definition
Hormonal therapies for hormone-dependent cancers — endocrine therapy for breast cancer and androgen deprivation therapy (ADT) for prostate cancer — significantly increase cardiovascular morbidity and mortality. CV risk varies by drug class, combination partner, treatment duration, baseline CV risk factors, and sex/racial background.
Key Concepts
Endocrine Therapy for Breast Cancer — CV Risk by Drug Class
Tamoxifen (SERM)
- Net arterial CVD effect: neutral to cardioprotective — reduces LDL-C and Lp(a); 3 placebo-controlled RCTs show cardioprotective effect (pooled RR 0.67, 95% CI 0.45–0.98)
- Significantly increases VTE — 41% higher DVT/PE risk vs. aromatase inhibitors; monitor for pulmonary hypertension long-term
- Increases body fat, hepatic steatosis, triglycerides, and diabetes risk
- Anticancer activity persists (unlike raloxifene) after discontinuation
- (sources/Hormonal-Rx-AHA-2021, rating: high)
Aromatase Inhibitors (anastrozole, letrozole, exemestane)
- Pooled RR 1.19 (95% CI 1.07–1.34) for overall CVD vs. tamoxifen (meta-analysis 8 RCTs); 30% higher MI risk (95% CI 1.11–1.53); 1.86× higher HF risk (UK cohort)
- Risk of dyslipidemia, hypertension, and accelerated atherosclerosis
- Anastrozole has the strongest CVD evidence (ATAC trial; pooled RR 1.24, 95% CI 0.98–1.56)
- Extending AI therapy beyond 5 years: OR 1.18 (95% CI 1.00–1.40) for CV events (meta-analysis n=16,349)
- AI use independently associated with >15% GLS decline on echocardiography
- (sources/Hormonal-Rx-AHA-2021, rating: high)
CDK4/6 Inhibitor Combinations
| Combination |
Key CV Toxicity |
Incidence |
Trial |
| Letrozole + ribociclib |
QTc >480 ms |
3.3% |
MONALEESA-2/7 |
| Fulvestrant + ribociclib |
QTc >480 ms |
5.6% |
MONALEESA-3 |
| Tamoxifen + ribociclib |
QTc >480 ms |
>5% |
MONALEESA-7 — avoid this combination |
| AI + palbociclib |
Hypertension grades 1–3 |
6% |
PALOMA-1/3 |
| AI/fulvestrant + abemaciclib |
No significant CV effects |
— |
MONARCH 1/2 |
- CDK4/6 meta-analysis: overall CV toxicity RR 1.39 (P=0.01) vs. endocrine therapy alone
- QT prolongation/VTE predominantly with ribociclib; hypertension predominantly with palbociclib; AF also reported with CDK4/6 combinations
- (sources/Hormonal-Rx-AHA-2021, rating: high)
mTOR and PI3K Inhibitor Combinations
- Everolimus + exemestane (BOLERO-2, n=724): Metabolic syndrome in >30% — hypertriglyceridemia, dyslipidemia, hyperglycemia; class effect of all mTOR inhibitors; especially high risk with pre-existing type 2 diabetes
- Alpelisib + fulvestrant (SOLAR-1, n=572): Grade 3 hyperglycemia in 36.6% vs. 0.7% placebo; >40% had grade 2–3 hyperglycemia
- (sources/Hormonal-Rx-AHA-2021, rating: high)
Ovarian Function Suppression (OFS) and Fulvestrant
- OFS (GnRH agonist or oophorectomy): 1.35× higher dyslipidemia risk; HR 1.16 for arrhythmia vs. natural menopause; theoretical increased CVD risk from early estrogen depletion in premenopausal women
- Fulvestrant: minimal cardiotoxicity; no significant VTE or hypertension increase vs. anastrozole
- (sources/Hormonal-Rx-AHA-2021, rating: high)
Androgen Deprivation Therapy (ADT) for Prostate Cancer
GnRH Agonists (leuprolide, goserelin, triptorelin, histrelin)
- Cardiometabolic effects: ↑ LDL-C and triglycerides, ↑ visceral fat, ↓ lean mass, ↑ insulin resistance, ↑ HbA1c, endothelial dysfunction, prothrombotic state, arterial wall thickening
- Population studies: stroke HR 1.2 (95% CI 1.12–1.28); MI HR 1.20 (95% CI 1.05–1.38) vs. no ADT
- Meta-analysis of 8 RCTs: no significant CV death increase (RR 0.93, NS) — severely underpowered; CV was not a primary endpoint
- (sources/Hormonal-Rx-AHA-2021, rating: high)
GnRH Antagonists — Preferred in Men with Pre-existing CVD
- Immediate testosterone suppression without surge; lower FSH levels → lower CV event rates
- HERO trial (relugolix vs. leuprolide): Major CV events 2.9% vs. 6.2% (HR 0.46, 95% CI 0.24–0.88) at 12 months
- Pooled analysis of 6 phase 3 RCTs: HR 0.44 (95% CI 0.26–0.74) for CV events vs. agonists
- ESC 2022 (Class IIa/B): GnRH antagonists preferred in men with pre-existing symptomatic CAD
- (sources/Hormonal-Rx-AHA-2021, rating: high)
Androgen Receptor Antagonists and Testosterone Synthesis Inhibitors
| Agent |
Key CV Toxicities |
| Enzalutamide |
Hypertension 7–13%; ischemic heart disease; fatal MI <1%; CV events leading cause of death in phase 3 nonmetastatic PCa trial (2% vs. <1% placebo) |
| Abiraterone |
Hypertension; hypokalemia; peripheral edema/fluid retention; arrhythmias; QT prolongation; angina; HF (must give with steroid replacement) |
| Apalutamide |
Hypertension; peripheral edema; ischemic heart disease; MI; QT prolongation |
| Darolutamide |
Ischemic heart disease; cardiac failure; hypertension |
| Bicalutamide |
Peripheral edema; hypertension; angina; MI; HF |
- Newer AR-directed agents meta-analysis: RR 1.36 (95% CI 1.13–1.64) for adverse CV events vs. no exposure
- Patients with ≥3 CV comorbidities on abiraterone/enzalutamide: 1.56× higher all-cause mortality vs. no CV comorbidities
- (sources/Hormonal-Rx-AHA-2021, rating: high)
CV Monitoring Framework
Breast Cancer (Endocrine Therapy)
- Baseline ECG recommended — particularly before CDK4/6 inhibitor combination initiation
- Monitoring intensity guided by prior cardiotoxic therapy (anthracyclines, trastuzumab, RT)
- Annual ECG + biomarkers (BNP, troponin) + echocardiography including GLS in appropriate patients
- SERM patients: monitor for hypertension, DVT/PE, and long-term pulmonary hypertension
- AI patients: serial lipid profile; monitor for dyslipidemia, atherosclerosis, and HF
Prostate Cancer (ADT)
- Baseline: comprehensive CV history; tobacco, obesity, metabolic syndrome, diabetes, hypertension, dyslipidemia
- Serial: lipid profile, BMI, waist-to-hip ratio, HbA1c, blood pressure
- Follow AHA secondary prevention guidelines in men with pre-existing CVD on ADT
ABCDE Cardioprotection Algorithm
- A — Awareness of heart disease risks; Aspirin (individualized, high-risk patients only)
- B — Blood pressure management
- C — Cholesterol control; Cigarette/tobacco cessation
- D — Diet and weight management; Dose of chemo/RT optimization; Diabetes prevention/treatment
- E — Exercise; ECG; Echocardiogram
- (sources/Hormonal-Rx-AHA-2021, rating: high)
Racial/Ethnic Disparities
- Black women with breast cancer: 25% greater CVD RR vs. White women; 6× higher HF/CVD death risk (SEER)
- Black men with prostate cancer: 13% greater CVD RR vs. White men
- Black patients initiating AI therapy have higher baseline ASCVD risk scores and more CV risk factors at baseline
- Structural racism and social determinants of health are likely root causes — multilevel interventions required
- (sources/Hormonal-Rx-AHA-2021, rating: high)
Contradictions / Open Questions
- Whether higher CVD risk with AIs vs. tamoxifen reflects AI toxicity or tamoxifen cardioprotection is unresolved — 3 placebo-controlled RCTs demonstrate tamoxifen is itself cardioprotective; this context is often missing from AI-focused analyses. (sources/Hormonal-Rx-AHA-2021, rating: high)
- GnRH antagonist superiority debate: HERO trial strongly favors relugolix (HR 0.46); PRONOUNCE trial (stopped early; optimal CVRF management in both groups) showed no MACE difference — whether antagonists reduce CV events beyond optimal CV risk factor management is uncertain. (sources/Hormonal-Rx-AHA-2021, sources/Cardio-Oncology-ESC-2022)
- No definitive prospective guidelines for monitoring or managing hormonal therapy–related cardiotoxicity; the ESC 2022 cardio-oncology guideline provides the most structured guidance but acknowledges evidence gaps. (sources/Hormonal-Rx-AHA-2021)
- Duration-specific CV effects are not well characterized — cancer outcome trials report at fixed timepoints and are underpowered for CV endpoints; when CV risk accumulates vs. plateaus with prolonged therapy is unknown. (sources/Hormonal-Rx-AHA-2021)
- Racial/ethnic CV risk differences may be confounded by baseline CVD risk disparities from health inequities rather than differential drug response — the two cannot be separated in current data. (sources/Hormonal-Rx-AHA-2021)
Connections
Sources